AzTrials
AzTrials

Osteoarthritis, KneeNCT02290275

Creatine, Exercise and Inflammatory Markers in Knee Osteoarthritis

A study testing Creatine and Walking Exercise in people with Osteoarthritis, Knee, run by University of Manitoba at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this research project is to determine the effectiveness of creatine supplementation and supported low-load walking exercise for managing systemic inflammatory biomarkers and joint symptoms in individuals diagnosed with chronic symptomatic knee osteoarthritis. Read more about this study

Who is it for?
Ages 45 to 65 years
Conditions the study is for
Osteoarthritis, Knee
What is being tested?
Creatine and Walking Exercise
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
30 participants
Where
1 siteCanada
Study dates
Jan 2015to Apr 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • (1) Ages 45-65; (2) Body mass index (BMI) over 25 kg/m2; (3) Knee pain when performing normal activities of daily living (walking, squatting, or kneeling); (4) Kellgren \& Lawrence grades II \& III radiographic evidence of mild to moderate knee osteoarthritis in one or both knees.

Who cannot join

  • (1) Radiographic evidence of severe knee osteoarthritis; (2) History of traumatic hip, knee, or ankle injury or surgery; (3) Use of crutches or a walking aid during ambulation; (3) History of medical conditions that prevent physical activity; (4) Unable to provide consent due to language barrier or mental status; (5) History of diabetes, cardiovascular disease, or screen positive for ankylosing spondylitis, psoriatic arthritis, chronic reactive arthritis, or renal problems requiring peritoneal dialysis or hemodialysis; (6) Unwillingness or inability to return for follow-up appointments.

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Alison Longo

    Winnipeg, Manitoba, R3M 3E4

Other trials in Canada

About this study

The goal of this research project is to determine the effectiveness of creatine supplementation and supported low-load walking exercise for managing systemic inflammatory biomarkers and joint symptoms in individuals diagnosed with chronic symptomatic knee osteoarthritis. The central hypothesis of this investigation is that creatine supplementation and exercise will significantly lower systemic biomarkers of inflammation in patients diagnosed with knee osteoarthritis.

Read the detailed description

Participants will provide informed consent, complete participant information and knee demographic forms, and undergo radiographic evaluation to confirm eligibility. Baseline evaluation of (1) systemic inflammation; and (2) knee joint pain and function will be completed. Following baseline evaluation, participants will be randomly assigned to 1 of 3 groups using online software available at http://www.randomizer.org/:

  1. Exercise group: Participants will exercise for 30 minutes under low-load walking conditions 3x per week for 12 consecutive weeks on a Lower Body Positive Pressure (LBPP) treadmill (Alter-G Inc - Menlo Park, CA) at a set speed of 3.1 mph at 0⁰ incline. The initial five minutes of each exercise session will be used as a warm-up to allow the participant to reach their target heart rate, to accommodate to walking on the treadmill's belt surface, and to facilitate adjustment of the LBPP within the treadmill's air chamber to a percentage of unweighting that eliminates or substantially reduces the participant's acute knee pain for the duration of the 30 minute walking session. Subjects will be blinded to the amount of LBPP used to un-weight them during each low-load walking session.
  2. Creatine group: Participants will supplement their regular diet with creatine monohydrate for 12 consecutive weeks. In week #1, participants will ingest 5 grams of creatine monohydrate 4x per day for a total ingestion of 20 grams per day. For the remaining 11 weeks, participants will consume 5 grams of creatine monohydrate per day to maintain the increased concentration of creatine.
  3. Placebo group: Participants in the placebo group will supplement their regular diet with maltodextrin (an inert sugar based molecule) for 12 consecutive weeks. In week #1, participants will ingest 5 grams of maltodextrin 4x per day for a total ingestion of 20 grams per day. They will then ingest 5 grams of maltodextrin per day for the remaining 11 weeks.

All data collection will take place at the Pan Am Clinic, a multidisciplinary tertiary care hospital and research facility that serves as the Winnipeg Regional Health Authority's "Centre of Excellence for Musculoskeletal Injury Assessment and Treatment". This project will utilize the combined assets of University of Manitoba and Pan Am Clinic to access medical resources that are used on a daily basis for the diagnosis, treatment, and long term management of patients with knee OA. All participants will undergo follow-up evaluation 13 weeks after their initial baseline evaluation.

Aim #1: Determine if knee OA systemic inflammation is significantly decreased following completion of a 12 week creatine supplementation or low-load treadmill walking exercise regimen.

Hypotheses:

  • There will be a significant decrease in systemic inflammation following completion of a 12 week creatine supplementation program.
  • There will be a significant decrease in systemic inflammation following completion of a 12 week low-load walking exercise program.
  • There will be no decrease in systemic inflammation following completion of a 12 week placebo supplementation program.

Primary Outcome Measures: Systemic inflammation will be evaluated by obtaining venous blood samples from the participants. Blood samples (approximately 20 mL) will be drawn by venipuncture from the antecubital vein into cooled (4°C) vacutainer tubes containing EDTA under sterile conditions. After inversion, tubes will be centrifuged at 1065g for 15 minutes at 4°C. Approximately 8 mL of plasma will be aliquoted into Eppendorf tubes (8 x 1 mL per tube) and frozen at -80°C until analysis. All plasma samples will be evaluated for C-reactive protein, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-10 (IL-10) using an enzyme linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions. All assays will be analyzed in duplicate within the same microplate to reduce variation. Serum will be obtained by drawing a blood sample by venipuncture into vacutainer serum separator tubes. This serum will be used to analyze the serum cartilage oligomeric matrix protein (sCOMP) using an ELISA kit according to the manufacturer's instructions.

Aim #2: Determine if knee OA joint pain and function are significantly altered following completion of a 12 week creatine supplementation or low-load treadmill walking exercise regimen.

Hypotheses:

  • There will be a significant decrease in knee OA joint pain and dysfunction following completion of a 12 week creatine supplementation program.
  • There will be a significant decrease in knee OA joint pain and dysfunction following completion of a 12 week low-load walking exercise program.
  • There will be no significant decrease in knee OA joint pain and dysfunction following completion of a 12 week placebo supplementation program.

Primary Outcome Measures: Knee pain during normal activities of daily living (ADLs) will be evaluated using the Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaire. The KOOS is a self-administered, knee-specific questionnaire that is designed to measure OA patient's knee pain over the previous seven-day period. Testing indicates that it is a valid, highly reliable and responsive measurement tool for evaluating changes after different OA interventions.

Secondary Outcome Measures: Bilateral knee joint function and physical health will be evaluated through the following measures both pre and post study:

  1. Goniometric assessment of knee joint range of motion (ROM) is a clinically accepted procedure for evaluating joint function. It allows the reliable and accurate quantification of movement using linear (cm) and angular units (degrees).
  2. Isokinetic evaluation of thigh muscle strength is the gold standard method used to quantify thigh muscle strength about an OA knee joint in both longitudinal and clinical investigations, as well as to examine the effect of creatine or exercise interventions on patients with knee OA.
  3. Measurement of cardiovascular (CV) capacity via maximum volume of oxygen uptake (VO2 max) testing. VO2 max testing assesses the maximum amount of oxygen that a person can consume per minute at a maximum work rate and is considered the best measure of cardiovascular health.
Being tested
Creatine, Walking Exercise, placebo (maltodextrin)
Medical subject headings
Osteoarthritis, Knee

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CreatineDietary supplement

    Subjects will supplement their regular diet with 20 grams of creatine for 1 week and then 5 grams of creatine for the following 11 weeks.

  • Walking ExerciseOther

    Subjects will walk on a specialized treadmill that lowers the impact of walking by taking up to 80% of their body weight away. The subjects will exercise by walking on this treadmill at 3.1 mph, 3 days per week for 30 minutes per day for 12 weeks.

  • placebo (maltodextrin)Dietary supplement

    Subjects will supplement their regular diet with 20 grams of maltodextrin for 1 week and then 5 grams of maltodextrin for the following 11 weeks.

Study groups in NCT02290275
Study groupRoleWhat they receive
PlaceboPlacebo comparatorThe subjects in this arm will receive 20 grams of a placebo (maltodextrin) for 1 week and then 5 grams of placebo (maltodextrin) for 11 weeks in addition to their regular diets.
Receives: Dietary Supplement: placebo (maltodextrin)
CreatineExperimentalThe subjects in this arm will receive 20 grams of creatine for 1 week and then 5 grams of creatine for 11 weeks in addition to their regular diets.
Receives: Dietary Supplement: Creatine
Walking ExerciseExperimentalThe subjects in this arm will receive a walking exercise program on a motorized treadmill where they will walk for 30 minutes at 3.1 mph, 3 days per week for 12 weeks.
Receives: Other: Walking Exercise

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. C-reactive protein

    Measured: 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Nov 2014 (estimated)
  2. Study startJan 2015
  3. Primary completionApr 2016
  4. Study completionApr 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02290275
Sponsor's protocol ID
E2014:117
Status last verified
May 2016
First submitted
10 Nov 2014
Last updated
16 May 2016
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Creatine and Walking Exercise in people with Osteoarthritis, Knee, run by University of Manitoba at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 May 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

C-reactive protein (time frame: 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 May 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in